BioSpace News Archive

Clene Inc. along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc. announced a $1 million grant award from the Maryland Department of Housing and Community Development to further support the redevelopment of the Clene manufacturing facility in Elkton, MD.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced new data from investigator-led studies of mitapivat, a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes, in adults with sickle cell disease.

Imara Inc today announced the presentation of 12-month data from its Phase 2a open-label extension (OLE) trial for tovinontrine (IMR-687) as a potential treatment for sickle cell disease (SCD) at the American Society of Hematology (ASH) Annual Meeting, held December 11-14, 2021.

Gritstone bio, Inc. today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc., announced positive results of an interim analysis of overall survival from the pivotal study “CHOICE-01”, a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus standard-of-care chemotherapy as the first-line treatment of advanced squamous or non-squamous non-small cell lung cancer.

atai Life Sciences N.V. today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021.

Q32 Bio today announced preclinical data for the Company’s lead program for innate immunity, ADX-097.

Biohaven Pharmaceutical Holding Company Ltd. announced today that NURTEC ODT (rimegepant) 75 mg was approved by the Ministry of Health of Israel for the preventive treatment of episodic migraine in adults.

Nevro Corp. today announced that three abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) were accepted for podium presentation at the 2022 North American Neuromodulation Society Annual Meeting (NANS 2022) and will be presented during the late-breaking plenary sessions on January 15, 2022.

Year-end net profit of $23.5 million or $0.91 per share which includes net income from the sale of the AquaGuard operations.